SPX3,693.23-64.76 -1.72%
DIA295.86-4.66 -1.55%
IXIC10,867.93-198.88 -1.80%

BRIEF-I-Mab Announces Approval From China CDE To Initiate Phase 3 Registrational Study

BRIEF-I-Mab Announces Approval From China CDE To Initiate Phase 3 Registrational Study

Reuters · 09/13/2022 10:35
BRIEF-I-Mab Announces Approval From China CDE To Initiate Phase 3 Registrational Study

- I-Mab IMAB.O:

  • I-MAB ANNOUNCES APPROVAL FROM CHINA CDE TO INITIATE PHASE 3 REGISTRATIONAL STUDY OF LEMZOPARLIMAB IN COMBINATION WITH AZACITIDINE IN HIGHER-RISK MYELODYSPLASTIC SYNDROME

  • I-MAB - ON TRACK TO INITIATE STUDY AS PLANNED

Source text for Eikon: ID:

Further company coverage: IMAB.O


((Reuters.Briefs@thomsonreuters.com;))